We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
- Authors
Ou, Wei; Li, Ning; Wang, Si‐Yu; Li, Jian; Liu, Qian‐Wen; Huang, Qun‐Ai; Wang, Bao‐Xiao
- Abstract
<bold>Background: </bold>The objective of this phase 2 trial was to assess the efficacy and safety of induction bevacizumab plus chemotherapy followed by surgery in patients with unresectable stage III lung adenocarcinoma.<bold>Methods: </bold>The authors investigated induction bevacizumab (7.5 mg/kg) plus pemetrexed (500 mg/m(2) and carboplatin (area under the receiver operating characteristic curve = 5) followed by surgery for patients with unresectable stage III lung adenocarcinoma ages 18 to 65 years. The patients received neoadjuvant therapy every 3 weeks for 4 cycles. Surgery was scheduled 3 to 4 weeks after the last neoadjuvant therapy; then, the medical team assessed each patient's resectability status. The primary endpoint was the resectability rate.<bold>Results: </bold>From April 2012 to April 2014, 42 patients were enrolled and received bevacizumab plus pemetrexed and carboplatin. Grade 3 or 4 induction-related AEs included fatigue in 5 patients, neutropenia in 4 patients, hypertension in 1 patient, anemia in 1 patient, and thrombocytopenia in 1 patient. One patient achieved a complete response, 22 achieved a partial response, 17 had stable disease, and 2 had progressive disease. After neoadjuvant therapy, 31 patients (73.8%) underwent surgery, including 11 who underwent pneumonectomy. Complete (R0) resection was achieved in 22 patients (52.4%). Reoperation was required in 1 patient because of a bleeding intercostal artery. No perioperative thromboembolic events or wound-healing problems were observed. The median event-free survival was 15.4 months, and the 1-year event-free survival rate was 56.1%.<bold>Conclusions: </bold>Treatment with neoadjuvant bevacizumab in combination with pemetrexed and carboplatin followed by surgery appears to be feasible and safe in patients with unresectable stage III lung adenocarcinoma. Cancer 2016;122:740-747. © 2015 American Cancer Society.
- Subjects
ADENOCARCINOMA; BEVACIZUMAB; PEMETREXED; CARBOPLATIN; NEUTROPENIA; DISEASE progression; ANTINEOPLASTIC agents; ANEMIA; CLINICAL trials; COMBINED modality therapy; COMPARATIVE studies; FATIGUE (Physiology); HYPERTENSION; LUNG tumors; RESEARCH methodology; MEDICAL cooperation; PNEUMONECTOMY; RESEARCH; SURVIVAL; THROMBOCYTOPENIA; TUMOR classification; EVALUATION research
- Publication
Cancer (0008543X), 2016, Vol 122, Issue 5, p740
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/cncr.29800